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1. Introduction
The complete decoding of the human genome in 2003 raised expectations for targeted drug
design and personalized medical care based on genetic information and also for gene therapy
of disease. To reach these goals, it is necessary to develop new technologies capable of
identifying drug-target genes from enormous volumes of genome information, validating the
biological functions, and comprehensively analyzing protein functions and interactions that
have hitherto been studied individually. We first developed an mRNA display, termed the in
vitro virus (IVV) method [1-3], and a C-terminal protein labeling method [4,5]that provided
the required technology (Fig. 1).
The IVV method, originally developed for evolutionary protein engineering based on in vitro
translation systems, was subsequently applied for the analysis of various protein interactions.
In the IVV method, the genotype molecule (mRNA) is linked to the phenotype molecule (pro‐
tein) through puromycin in a cell-free translation system [3]. We have developed this method
into a stable, efficient, and high-throughput technique that allows simple selection without any
requirement for post-translational work [3], unlike previous systems. An additional technolog‐
ical advance is the elimination of the need to express and purify bait proteins for downstream
protein‑protein interaction studies. Our totally in vitro cell‑free co translation system provides a
simpler solution that is suitable for high‑throughput, genome‑wide analysis, as baits are syn‐
thesized within each reaction. Moreover, as cotranslation of bait and prey proteins is favorable
for the formation of multi‑protein complexes, this approach offers a better chance to obtain a
more comprehensive data set, including both direct and indirect interactions, in a single experi‐
ment. Here, we provide an overview of this system and discuss its advantages for analyses of
various protein interactions including protein-protein, DNA(RNA)-protein, peptide-protein,
drug-protein, and antigen-antibody interactions.
© 2013 Tabata et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. In vitro virus(IVV) formation and C-terminal labeling on the ribosome. Puromycin at the 3’-terminal end of a
spacer ligated to mRNA can enter the ribosomal A-site to bind covalently to the C-terminal end of the encoded full-
length protein in the ribosomal P-site. The same property of puromycin to develop a highly specific labeling system for
proteins was also utilized, in which puromycin derivatives bearing a fluorescein moiety are used to label the C-termi‐
nal end of a full-length protein.
The antibiotic puromycin [6], which is an analogue of the 3’ end of TyrtRNATyr [7], acts in
both prokaryotes and eukaryotes [8] as an inhibitor of peptidyl transferase [9]. It has two modes
of inhibitory action. The first is by acting as an acceptor substrate that attacks peptidyl-tRNA
(donor substrate) in the P site to form a nascent peptide [10]. The second is by competing with
aminoacyl-tRNA for binding to the A’ site, which is the binding site of the 3’ end of aminoacyl-
tRNA within the peptidyl transferase active site [11]. It has been reported that the polypeptides
released by puromycin are not full-length proteins [9]. Similarly, it has been shown that
growing peptide chains on ribosomes are transferred to the α-amino group of puromycin,
which interrupts the normal reaction of peptide bond formation [10]. Therefore, these con‐
ventional studies suggested that puromycin is a non-specific inhibitor of protein synthesis as
a result of competition with aminoacyl-tRNA. However, since most of the studies on puro‐
mycin were performed at relatively high concentrations, the behavior of puromycin at lower
concentrations was still an open question at that time. It had been reported that full-length
protein that fails to be released from ribosomes at the final stage of protein synthesis, requires
treatment with puromycin or RFs to be released [12]. These results led us to hypothesize that
puromycin at very low concentrations, which would not effectively compete with aminoacyl-
tRNA [2], might act as a noninhibitor and bond specifically to full-length protein at the stop
codon. Indeed, we confirmed that puromycin and its derivatives bond only to full-length
protein at very low concentrations (such as 0.04 μM), where they are “non-inhibitors” of
protein synthesis, by using 32P-labeled rCpPuro (2’-ribocytidylyl-(3'→5')- puromycin) in an E.
coli S30 extract cell-free translation system [2]. Our results provided the first evidence that
specific bonding of puromycin to the full-length protein occurs at the stop codon during the
process of termination of protein synthesis at very low concentration. In other words, puro‐
mycin at sufficiently low concentrations only has the opportunity to be bonded to proteins at
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a stop codon, where it does not need to compete with aminoacyl-tRNA. Since termination is
a relatively slow step involving a translational pause in eukaryotes [13] and E. coli [14], it is
possible that puromycin even at very low concentrations can bind to the A' site, and compete
with RFs to release the full-length protein from ribosomes. Accordingly, under these condi‐
tions, puromycin can be incorporated specifically at the C-terminus of the full-length protein.
This concept is the basis of so-called puromycin technology [2,3]. The combination of this
puromycin technology with in vitro translation has yielded novel methods, such as IVV and
C-terminal labeling techniques, for protein selection and screening [15,16], fluorescence
labeling [2,5], and affinity purification (pull-down assay), as well as protein chips for proteo‐
mics [5,17], and superior methods for evolutionary protein engineering.
2. Application of the IVV method for analyzing various protein interactions
The IVV method is applicable for analyzing protein–protein [15,16,18,19] DNA(RNA)–protein
[20-22], peptide–protein [23-27], drug–protein [28, 29] and antigen–antibody [30,31] interac‐
tions. As a result, we are able to explore protein complexes, transcription factors, RNA-binding
proteins, bioactive peptides, drug-target proteins, and antibodies (antibodies will be discussed
later) (Fig. 2). library and conjugation with a polyethylene glycol (PEG) spacer with puromycin,
cell-free translation to form IVV and interaction of bait attached to beads and prey IVV library
to form complexes, IVV selection with bait, and RT-PCR to amplify mRNA tags. Selection
rounds are repeated until sufficient enrichment is obtained, followed by cloning and sequenc‐
ing, and protein sequences are decoded.
 
Figure 2. IVV selection based on cell-free co translation. The IVV selection procedure is composed of transcription
from a cDNA
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2.1. DNA-protein interaction
The specific  interactions  between cis-regulatory DNA elements  and transcription factors
are critical components of transcriptional regulatory networks [32,33]. The whole genome
and complete  cDNA sequences  contain  large  numbers  of  transcription factors  and their
binding  DNA  sequences,  and  thus  comprehensive  analysis  of  DNA-transcription  factor
interactions  is  expected  to  provide  a  deep  understanding  of  the  mechanisms  of  cell
proliferation,  developmental  processes  in  tissue  morphogenesis  and  disease.  Currently,
combined  use  of  chromatin  immunoprecipitation  (ChIP)  assay  with  DNA  microarrays
(ChIP-chip)[34] has become the most widely used high-throughput method for discover‐
ing  cis-regulatory  DNA elements  for  a  transcription  factor.  In  contrast,  development  of
high-throughput  methods for  discovering transcription factors  for  a  cis-regulatory DNA
element remains at an early stage. Although the yeast one-hybrid method [35] and phage
display [36] are attractive candidates, these methods are not easily scalable because of the
use  of  living  cells.  In  addition,  as  over-expression  of  transcription  factors  often  affects
cellular metabolism, such transcription factors are difficult to screen. In order to circum‐
vent these difficulties, we focused on a totally in vitro mRNA display technology such as
IVV method [1-3,15,16] for the discovery of DNA–protein interactions.
Comprehensive analysis of DNA–protein interactions is important for mapping transcrip‐
tional regulatory networks at a genome-wide level. We employed the IVV method for in
vitro selection of DNA-binding protein heterodimeric complexes [20]. Under improved
selection conditions using a TPA-responsive element (TRE) as a bait DNA, known interactors
c-fos and c-jun were simultaneously enriched about 100-fold from a model library (a 1:1:20 000
mixture of c-fos, c-jun and gst genes) after one round of selection. Furthermore, almost all of
the AP-1 family genes, including c-jun, c-fos, junD, junB, atf2 and b-atf, were successfully
selected from an IVV library constructed from a mouse brain poly A+ RNA after six rounds of
selection. These results indicate that the IVV selection system can identify a variety of DNA-
binding protein complexes in a single experiment. Since almost all transcription factors form
hetero-oligomeric complexes to bind with their target DNA, this method should be most useful
to search for DNA-binding transcription factor complexes.
2.2. Peptide–protein interaction
Peptides are powerful tools for disrupting protein-protein interactions because the large
interacting surfaces and the high specificity of these peptides lead to fewer adverse side effects
when they are used as pharmaceutical agents [37]. As previously reported, several peptides
that inhibit the MDM2-p53 interaction have been identified from randomized peptide libraries
using phage display [38]. Hu et al. identified a 12-amino-acid (aa) peptide (LTFEHYWAQLTS),
DI, that could inhibit not only the MDM2-p53 interaction, but also the MDMX-p53 interaction
more effectively than Nutlin-3, a small molecular inhibitor of the MDM2-p53 interaction [39].
An MDM2 homologue, MDMX is highly expressed in tumors, and it binds to and negatively
regulates p53 [40]. Furthermore, DI expressed with recombinant adenovirus as a thioredoxin-
fused protein could activate the p53 pathway both in vitro and in vivo. However, DI was not
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sufficiently optimized because it was selected by phage display from a 12-mer random library
(4.161,015 possible members) with a size of ∼108 that did not cover all of the possible sequences.
To overcome this problem, we performed in vitro selection of MDM2-binding peptides from
random peptide libraries using the IVV method [1-3,15]. This system based on cell-free
translation is a potent method for screening large peptide libraries (1013 unique members) and
is able to cover all of the possible sequences in a 10-mer random library. We applied the IVV
method to identify a highly optimized peptide that could disrupt the MDM2-p53 complex
from a random library containing all of the possible sequences by dividing the selection process
into two stages. We also verified that a selected peptide could inhibit the MDM2-p53 interac‐
tion in living cells and block tumor cell growth.
We identified an optimal peptide named MIP that inhibited the MDM2-p53 and MDMX-p53
interactions 29- and 13-fold more effectively than DI, respectively (Fig. 3) [23]. Adenovirus-
mediated expression of MIP fused to the thioredoxin scaffold protein in living cells caused
stabilization of p53 through its interaction with MDM2, resulting in activation of the p53
pathway. Furthermore, expression of MIP also inhibited tumor cell proliferation in a p53-
dependent manner more potently than did DI. These results show that two-stage, the peptide
selection by IVV method [1-3,15] is useful for the rapid identification of potent peptides that
target oncoproteins.
Bcl-XL, an antiapoptotic member of the Bcl-2 family, is a mitochondrial protein that inhibits
activation of Bax and Bak, which commit the cell to apoptosis, and it therefore represents a
potential target for drug discovery. Peptides have potential as therapeutic molecules because
they can be designed to engage a larger portion of the target protein with higher specificity.
We selected 16-mer peptides that interact with Bcl-XL from random and degenerate peptide
libraries using the IVV method [24]. The selected peptides have sequence similarity with the
Bcl-2 family BH3 domains, and one of them has higher affinity (IC50 = 0.9 μM) than Bak BH3
(IC50 = 11.8 μM) for Bcl-XL in vitro. We also found that GFP fusions of the selected peptides
specifically interact with Bcl-XL, localize in mitochondria, and induce cell death. Further, a
chimeric molecule, in which the BH3 domain of Bak protein was replaced with a selected
peptide, retained the ability to bind specifically to Bcl-XL. These results demonstrate that this
selected peptide specifically antagonizes the function of Bcl-XL and overcomes the effects of
Bcl-XL in intact cells. Thus, the IVV method is a powerful technique to identify peptide
inhibitors with high affinity and specificity for disease-related proteins.
The importin α/β pathway mediates nuclear import of proteins containing the classical nu‐
clear localization signals (NLSs). Although the consensus sequences of the classical NLSs
have been defined, there are still many NLSs that do not match the consensus rule and
many nonfunctional sequences that match the consensus. We identified six different NLS
classes that specifically bind to distinct binding pockets of importin α. By screening of ran‐
dom peptide libraries using the IVV method, we selected peptides bound by importin α and
identified six classes of NLSs, including three novel classes (Table 1). Two noncanonical
classes (class 3 and class 4) specifically bound to the minor binding pocket of importinα,
whereas the classical monopartite NLSs (class 1 and class 2) bound to the major binding
pocket. Using a newly developed universal green fluorescent protein expression system, we
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found that these NLS classes, including plant-specific class 5 NLSs and bipartite NLSs, fun‐
damentally require regions outside the core basic residues for their activity and have specif‐
ic residues or patterns that confer distinct activities between yeast, plants, and mammals.
Furthermore, amino acid replacement analyses revealed that the consensus basic patterns of
the classical NLSs are not essential for activity, and more unconventional patterns, including
redox-sensitive NLSs, were generated. These results explain the causes of NLS diversity.
The defined consensus patterns and properties of importin α-dependent NLSs provide use‐
ful information for identifying NLSs [25-27].
Figure 3. A multiple-sequence alignment of the selected peptides(upper) and inhibition of MDM2-p53 interactions by
synthetic peptides(lower). Peptide sequences selected from randomized mRNA displayed peptide libraries were
aligned using the ClustalW program. 12-mer peptides after five rounds of selection. Fixed amino acid residues are
shown in bold. Values below the displayed p5317–28 sequence indicate the position of amino acids in the p53 protein.
MDM2 was generated by an in vitro transcription reaction, bound to His6-p53 immobilized on copper-coated plates in
the presence of various concentrations of synthetic MIP(circle), DI (triangle), 3A (diamond) or p53 (square) peptides
and quantified by ELISA.
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αα
aSequence representation is as follows: (^DE), any amino acid exept Asp or Glu; X10-12, any 10-12 amino acids.
bFor more optimal patterns, acidic residues should be rich in the central linker region and rare in the terminal linker region,
whereas basic and hydrophobic residues should be rare in the central region and proline-rich in the terminal region.
Table 1. Consensus sequence of six classes of importin α-dependent NLS
2.3. Drug-protein interaction
Despite the introduction of newly developed drugs, such as lenalidomide and bortezomib,
multiple myeloma is still difficult to treat and patients have a poor prognosis. In order to find
novel drugs that are effective for multiple myeloma, we tested the antitumor activity of 29
phthalimide derivatives against several multiple myeloma cell lines. Among these derivatives,
2-(2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione (TC11) was found to be a potent
inhibitor of tumor cell proliferation and an inducer of apoptosis via activation of caspase-3, 8
and 9. This compound also showed in vivo activity against multiple myeloma cell line KMS34
tumor xenografts in ICR/SCID mice. To identify TC11-binding proteins, we used the IVV
method [1-3,15]. We first prepared a cDNA library derived from KMS34 cells, because our data
suggested that KMS34 cells were the most sensitive to TC11. As a bait, biotinylated TC11 was
immobilized on a microfluidic chip and TC11-binding proteins were selected. Although the
4-amino group of TC11, which was experimentally inferred to be critical for the activity, was
biotinylated via a linker, the biotinylation hardly affect the antitumor activity. Among 11
candidate TC11-binding proteins identified by the IVV method after 4 rounds of selection, we
focused on the nucleolar phosphoprotein nucleophosmin (NPM). Sequencing revealed that
three selected NPM clones, designated 1–183 NPM, encoded the 183 NH2-terminal amino acids
of NPM, which include the oligomerization domain and a part of the histone-binding domain.
The enrichment efficiency of the NPM clones was confirmed to be 104-fold after 4 rounds of
selection by RT-PCR. NPM is a multifunctional protein involved in both tumorigenesis and
tumor suppression [41]; for example, it regulates cell proliferation and centrosome dupulica‐
tion [42] and stabilizes oncoprotein Myc [43] and tumor-suppressor protein p53 [44]. Therefore,
we hypothesized that NPM is involved in TC11-induced apoptosis of tumor cells. Immuno‐
fluorescence and NPM-knockdown studies in HeLa cells suggested that TC11 inhibits
centrosomal clustering by inhibiting the centrosomal-regulatory function of NPM, thereby
inducing multipolar mitotic cells, which undergo apoptosis. NPM may become a novel target
for development of antitumor drugs active against multiple myeloma [28].
We screened 46 novel anilinoquinazoline derivatives for activity to inhibit proliferation of a
panel of human cancer cell lines. Among them, Q15 showed potent in vitro growth-inhibito‐
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ry activity towards cancer cell lines derived from colorectal cancer, lung cancer and multi‐
ple myeloma. It also showed antitumor activity towards multiple myeloma KMS34 tumor
xenografts in lcr/scid mice in vivo.  Unlike the known anilinoquinazoline derivative gefiti‐
nib,  Q15  did  not  inhibit  cytokine-mediated  intracellular  tyrosine  phosphorylation.  To
elucidate the mechanism through which Q15 inhibits proliferation of tumor cells, we set out
to identify Q15-binding proteins by means of the IVV method [1-3,15]. We prepared a cDNA
library derived from total RNA of human colon carcinoma SW480 cells, because, like other
tumor  cells,  SW480  cells  were  sensitive  to  Q15.  Proteins  that  bind  to  biotinylated  Q15
immobilized on beads were selected using the IVV method. From the library obtained after
5 rounds of selection, we analyzed the DNA sequences of 100 clones.  Among them, we
obtained  six  clones  of  a  fragment  of  the  Luzp5/NCAPG2  gene  encoding  hCAP-G2262-476
containing the HEAT (Huntingtin, elongation factor 3, a subunit of protein phosphatase 2A,
TOR lipid kinase) repeat domain. Although three other clones were obtained redundantly,
they were confirmed to be false-positive clones by means of binding assay (data not shown).
hCAP-G2 is a subunit of condensin II complex [45,46], which is regarded as a key player in
mitotic  chromosome  condensation  [47].  Immunofluorescence  study  indicated  that  Q15
compromises normal segregation of chromosomes, and therefore might induce apoptosis.
Thus, our results indicate that hCAP-G2 is a novel therapeutic target for development of
drugs active against currently intractable neoplasms [29].
3. Application of the IVV method for comprehensive interactome network
analyses
Interactome networks are essential for complete systems-level descriptions of cells. Large-scale
protein-protein interactions (PPIs) are integral in the analysis of topological and dynamic
features of interactome networks. We introduce large-scale interactome network analyses
using a combination of the IVV method and a biorobot for 50 human transcription factors (TFs).
Comprehensive analysis of PPIs is an important task in the field of proteomics, functional
genomics and systems biology. PPIs are usually analyzed by means of biochemical methods
such as pull-down assay and co-immunoprecipitation, yeast two-hybrid (Y2H) assay [35] and
phage display [36]. Recently, the combined use of mass spectrometry (MS) with an affinity tag
[48] has made biochemical methods more comprehensive and reliable. However, the testable
interaction conditions are restricted by the properties of the biological sources. The Y2H assay
is one of the major tools used in the discovery and characterization of PPIs [49]. However, the
results of Y2H analyses often include many false positives due to auto-activating bait or prey
fusion proteins [50] and interactions of proteins that are toxic to yeast cells cannot be examined.
Phage display, the most widely used display technology [51], is an effective alternative,
because the interactions between libraries and target proteins occur in vitro, allowing optimal
conditions to be used for many different target proteins. However, the detectability of very
low copy number proteins by phage display is still limited, because phage libraries are
produced in living bacteria [52]. Totally in vitro display technologies such as ribosome display
[53], the IVV method [1-3,15] and DNA display [54] can circumvent the above difficulties,
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because they do not need living cells. As a model bait protein, we chose the basic leucine zipper
(bZIP) domain of Jun protein, an important transcription factor, to screen Jun interactors from
a mouse brain cDNA library. By performing iterative affinity selection and sequence analyses,
we selected 16 novel Jun-associated protein candidates in addition to four known interactors.
By means of real-time PCR and pull-down assay, 10 of the 16 newly discovered candidates
were confirmed to be direct interactors with Jun in vitro. Furthermore, interaction of 6 of the
10 proteins with Jun was observed in cultured cells by means of co-immunoprecipitation and
observation of subcellular localization. These results demonstrate that this in vitro display
technology is effective for the discovery of novel protein–protein interactions and can con‐
tribute to the comprehensive mapping of protein–protein interactions.
Furthermore, in a single experiment using bait Fos, more than 10 interactors, including not
only direct, but also indirect interactions, were enriched. Further, previously unidentified
proteins containing novel leucine zipper (L-ZIP) motifs with minimal binding sites identified
by sequence alignment as functional elements were detected as a result of using a randomly
primed cDNA library. Thus, we consider that this simple IVV selection system based on cell-
free cotranslation could be applicable to high-throughput and comprehensive analysis of PPI
and complexes in large-scale settings involving parallel bait proteins.
Interactome networks are essential for complete systems-level descriptions of cells. Large-scale
PPIs are integral in the analysis of topological and dynamic features of interactome networks
[55]. Several attempts to collect large-scale PPI data have been initiated using various model
organisms [56-61] and were subsequently conducted in humans [62-64]. Traditionally, protein
interaction data are collected using high-throughput in vivo expression tools based on the yeast
two hybrid (Y2H; [49]) and tandem affinity purification-mass spectrometry (TAP-MS; [65])
methods. Experiments of this nature have provided large-scale PPI data, but they have only
generated information on interacting partners, without considering binding domains in detail.
In the field of systems biology, a further understanding of cellular networks will require more
complete data sets describing the underlying physical interactions between cellular compo‐
nents. Thus, it is important to identify not only the binding partners, but also the interacting
domains at the amino acid level [66]. In fact, the idea of mapping the interacting regions (IRs)
involved in a PPI has been previously suggested in connection with several large-scale screens
[67]. Our IVV method of analyzing PPIs [15,16] is well suited for large-scale, high-throughput
mRNA display of the domain-based interactome using a randomly primed cDNA library, and
we were able to achieve the first large-scale mapping of human IR data at the domain level for
TF-related protein complexes. Functional domains were easily extracted based on the identi‐
fied sequences using a randomly primed prey library as a non-biased representation [15]. Bait
mRNA templates were prepared in vitro [15], and large-scale IVV method was performed using
a biorobot that can simultaneously execute up to 96 selections. Fifty human TF-related proteins
were used as bait, and a human brain cDNA library was used as prey. A modified high-
throughput version of IVV selection was employed [15]. Integration of large-scale PPI data
with other data sets, such as 3D structural information [68] and expression data [69], is
necessary to identify the possible functions of interaction networks [68]. Large-scale IR data
sets are expected to reflect functional domains and to indicate the biological roles of the
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network without the need to integrate additional data. We confirmed the reliability and
accuracy of our data by performing pull-down assays [15] and by examining the overlap
between our results and known PPI domains using Pfam search [70]. The core data set (966
IRs; 943 PPIs) displayed a verification rate of 70%. Analysis of the IR data set revealed the
existence of IRs that interact with multiple partners (Fig. 4). Furthermore, these IRs were
preferentially associated with intrinsic disorder. This finding supports the hypothesis that
intrinsically disordered regions play a major role in the dynamics and diversity of TF networks
through their ability to structurally adapt to and bind with multiple partners. Accordingly,
this domain-based interaction resource represents an important step in refining protein
interactions and networks at the domain level and in associating network analysis with
biological structure and function.
    
Figure 4. A transcription factor network at the interaction region(IR) level developed using IVV data. Graphic expres‐
sion of the PPI network at the IR level(right). Interacting interfaces of the proteins, determined as IRs by IVV experi‐
ments, are drawn on the graph as diamond-shape nodes (IR nodes). Broken and solid lines indicate ‘intra-’ and ‘inter-’
protein edges, respectively. The graph contains 1,572 nodes (842 IR nodes and 730 protein nodes) and 842 intra-pro‐
tein edges. Note that overlapping IRs are merged into a single node in the constructed network. An example of an
underlying network graph at the IR level. Graphical expression of the FOS network at the protein level (upper left).
PPIs are simply expressed by nodes indicating proteins and edges that connect them. Graphical expression of the FOS
network at the IR level (lower left). A leucine zipper region of the FOS protein exclusively interacts with leucine zipper
regions of other proteins (JUN, JUNB, JUND and ATF2). In addition, a region distinct from the leucine zipper in the FOS
protein interacts with SMAD2.
4. Ultrahigh enrichment of antibodies by the IVV method on a microfluidic
chip
Rapid preparation of monoclonal antibodies with high affinity and specificity is required in
diverse fields from fundamental molecular and cellular biology to drug discovery and
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diagnosis [71]. In addition to classical hybridoma technology, in vitro antibody-display
technologies [30,53,72-75] are powerful approaches for isolating single chain Fv (scFv)
antibodies from recombinant antibody libraries. However, these display techniques require
several rounds of affinity selection (typically, the library size is 107~1012, while the enrichment
efficiency is 10~103-fold per round). Recently, microfluidic systems have been developed for
high-throughput protein analysis [76], since they offer the advantages of very low sample
volumes, rapid analysis, and automated recovery of captured analytes for further characteri‐
zation. However, there have been few attempts to combine microfluidic systems with in
vitro antibody-display technologies so far. We showed that a microfluidic system can be
combined with the IVV method [1-3,15] and employed for scFv selection from naïve and
randomized scFv libraries with ultrahigh efficiency of 106- to 108-fold per round [31].
4.1. In vitro selection of antibodies from a naïve scFv library
The IVV selection of scFv was performed on a Biacore microfluidic chip. Since the diversity of
the mouse scFv library prepared from mouse spleen poly A+ RNAs is estimated to be 106~108,
while IVV method [15] allows screening of ~1012 molecules, we also introduced random point
mutations into the scFv library. We chose p53 (human tumor suppressor protein) and MDM2
(human murine double minute) proteins as model antigens that were immobilized on the
Biacore sensor chip. The selection experiment was performed on the microfluidic chip, and
selected scFv genes were amplified by reverse transcription (RT)-PCR and identified by
cloning and sequencing. Unexpectedly, the recovered anti-p53 and anti-MDM2 scFv sequences
converged on a single sequence and two sequences, respectively, after only two rounds of
selection. These clones showed high affinity, but also low antigen-specificity, in pull-down
assays, and so we examined the clones obtained after a single round of selection in each case.
When the binding activities of 29 (anti-p53) and 20 (anti-MDM2) clones with distinct sequences
were examined by means of pull-down assays, P1-93 and M1-19 showed high specificity
against the respective antigens among p53, MDM2 and BSA (Fig. 5A). The amino-acid
sequences of P1-93 and M1-19 are shown in Fig. 5B. In competitive ELISA, both clones dose-
dependently inhibited the ELISA signal (Fig. 5C), and Scatchard plots revealed that the KDs of
P1-93 and M1-19 were 22 nM and 5.9 nM, respectively. The KDs of P1-93 and M1-19 were also
determined by surface plasmon resonance (SPR) as 12 nM and 4.3 nM, respectively (Fig. 5D).
The values obtained by the two different methods are similar.
4.2. In vitro evolution of scFv
Further, we performed in vitro evolution of scFv with higher affinity against MDM2 from a
randomly mutated M1-19 scFv library. We applied on-rate or off-rate selection as a selection
pressure for in vitro affinity maturation with the Biacore instrument: the on-rate selection was
performed by controlling flow rate, and the off-rate selection was carried out by using a
prolonged washing process on the sensor chip. After one round of selection, the recovered
scFv genes were cloned and sequenced, and the KDs were evaluated by competitive ELISA
(Figs. 6A and 6D ). We obtained four mutants with higher affinity for MDM2 (KD = 0.7-3.8 nM)
than the progenitor M1-19 from 22 distinct clones. The strongest binder, M1-19a, was con‐
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firmed to have a higher on-rate and lower off-rate than M1-19 by SPR (Fig. 6B) and was also
confirmed to recognize only the antigen protein MDM2 in crude cell lysates by Western
blotting (Fig. 6C). These results indicated that the selected scFv had high enough affinity and
specificity for practical use. Although the mutations of the selected scFvs were distributed
among the whole sequences and no "consensus" mutations were identified, the mutation
Y100bH within VH CDR3 may contribute to the improved affinity and specificity, because this
region is usually important for binding with antigens.
4.3. Ultrahigh efficiency of protein selection
Surprisingly, our results indicated that positive clone(s) were efficiently enriched through only
one or two rounds of selection from a large library containing ~1012 molecules, implying
ultrahigh efficiency of the method. To estimate the enrichment efficiency, we performed model
experiments using a mixture of two kinds of scFv genes. The P1-93 (anti-p53) or M1-19 (anti-
MDM2) gene was mixed with an anti-fluorescein scFv gene [30]('Flu' as a negative control) at
a ratio of 1:102, 1:104, 1:106 or 1:108, and subjected to one round of the IVV selection on the sensor
 
Figure 5. The selected scFvs anti-p53 P1-93 and anti-MDM2 M1-19. (A) Pull-down assays of the anti-p53 scFv P1-93
(top) and anti-MDM2 scFv M1-19 (bottom) using p53-, MDM2- or BSA-immobilized beads. Recovered scFv with FLAG-
tag was detected with the anti-FLAG antibody. (B) Predicted amino-acid sequences of the VH (black bar) and VL (gray
bar) regions of anti-p53 scFv P1-93 and anti-MDM2 scFv M1-19. (C) Competitive ELISA. P1-93 or M1-19 was pre-incu‐
bated with a competitor (0~200 nM free antigen) and allowed to bind to antigen-immobilized plates. After washing,
remaining scFvs were detected with the anti-T7 tag antibody. (D) Biacore sensorgrams of the purified P1-93 (left: 31
kDa) and M1-19 (right: 32 kDa) using a p53- (blue lines: 55 kDa) or MDM2-immobilized (red lines: 66 kDa) sensor chip.
The measurements were performed under conditions of 450 RU of the ligand and at a flow rate of 60 µl/min. To de‐
termine dissociation constants, three different concentrations (35, 64, and 136 nM for P1-93 and 27, 50, and 75 nM
for M1-19) of the monomeric scFvs were injected.
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chip. The selection of the 1:106 mixture of P1-93:Flu genes and the 1:108 mixture of M1-19:Flu
genes each resulted in a roughly 1:1 final gene ratio (Fig. 7A), indicating enrichment efficiencies
of 106- and 108-fold per round, respectively. Furthermore, we confirmed that not only protein-
protein (antigen-antibody) interactions, but also protein-DNA and protein-drug interactions
were selected by our method with high enrichment efficiencies of >106-fold (Figs. 7B and 7C).
Since the enrichment efficiencies of these model experiments with a usual agarose resin were
only 10~103-fold per round, the enrichment efficiency was improved 103~105-fold over previous
methods. Furthermore, we confirmed that the IVV system using a photocleavable linker
between mRNA and protein is useful for in vitro selection of epitope peptides, recombinant
antibodies, and drug-receptor interactions [77].
Although Biacore instruments have so far been utilized mainly to analyze biomolecular
interactions by SPR, a few researchers have used this approach to fish for affinity targets from
a randomized DNA library [78], phage-displayed protein libraries [79,80], or a ribosome-
displayed antibody library [81]. However, the enrichment efficiency in these applications was
not high. Why, then, was ultrahigh efficiency achieved in the present protein selection by IVV
method? The IVV is a relatively small object pendant from its encoding RNA moiety, which
 
Figure 6. In vitro evolution of anti-MDM2 scFv M1-19. (A) Dissociation constants (KDs) of M1-19 (red circle) and the
four mutant scFvs (green circles) were obtained by means of Scatchard plots of the competitive ELISA data. (B) Biacore
sensorgrams of the mutant M1-19a (the amount of immobilized antigen was 450 RU). M1-19a had a higher on-rate
and lower off-rate (ka = 2.5 x 105/Ms, kd = 8.6 x 105/s, KA = 3.0 x 109/M, KD = 0.34 nM) than the progenitor M1-19 (ka =
5.5 x 104/Ms, kd = 2.3 x 104/s, KA = 2.4 x 108/M, KD = 4.3 nM; see Fig. 5D: red lines on right side). (C) Recombinant p53
and MDM2 proteins (10 and 25 ng), and HEK-293 cell lysates (1 and 2.5 µg) were analyzed by Western blotting using
M1-19a (left) or commercially available anti-MDM2 2A10 (right) as a control, respectively. (D) Predicted amino-acid
sequences of the VH (black bar) and VL (gray bar) regions of the mutant scFvs M1-19a-d.
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is about ten times larger. Thus, nonspecific adsorption of RNA on solid surfaces is potentially
significant. The matrix of the Biacore sensor chip consists of carboxymethylated dextran
covalently attached to a gold surface and poorly binds nucleic acid molecules, since both
materials are negatively charged. In contrast, phage display and ribosome display involve
large protein moieties (coat proteins or ribosome), so the use of the sensor chip may not
improve the enrichment efficiency in these cases.
It should be noted that the ultrahigh enrichment efficiency made it difficult to set the number
of selection rounds at a level that is appropriate to remove all non-binders as well as to pick
all binders with various affinities from a library. If the number of selection rounds is too small,
many negative sequences will be cloned; on the other hand, excess rounds of selection will
yield only a single sequence with the highest affinity. In this study, we obtained 20-30 different
sequences, including P1-93 and M1-19, with high antigen-specificity after a single round of
selection, while we obtained only one or two negative sequences with high affinity but low
antigen-specificity from the 106-108 library after two (probably excess) rounds of selection
(>1012-fold).
In summary, we achieved ultrahigh efficiencies (106~108-fold per round) of protein selection
by IVV method with the microfluidic system. We obtained scFvs with high affinity and
specificity from a naïve library by IVV selection for the first time. It took only three days to
perform each selection experiment, including activity evaluation by ELISA. Although prepa‐
ration of target materials of high quality is required, we anticipate this simple method to be a
starting point for a versatile system to facilitate high-throughput preparation of monoclonal
antibodies for analysis of proteome expression and detection of biomarkers, high-throughput
 
Figure 7. IVV selection of protein interactions on the Biacore sensor chip. (A) The P1-93 (912 bp: column 1 top) or
M1-19 (936 bp: column 1 bottom) gene was mixed with an anti-fluorescein scFv gene [30](Flu: 888 bp: column 2) at a
ratio of 1:102 (column 3), 1:104 (column 4), 1:106 (column 5) or 1:108 (column 6). The mixtures were subjected to IVV
selection on the sensor chip conjugated with antigens p53 (top) or MDM2 (bottom). The RT-PCR products amplified
from fractions after one round of selection were analyzed by agarose gel electrophoresis. (B) In vitro selection of pro‐
tein-DNA interactions was performed using a mixture of three genes with N-terminal T7 tag and C-terminal FLAG-tag
coding sequences: c-fos (349 bp), c-jun (394 bp), gst (597 bp). The template RNAs of c-fos, c-jun and gst (negative
control) were mixed at a ratio of 1:1:106. The mixtures were translated and the resulting IVV libraries were selected on
the sensor chip conjugated with bait DNA (AP-1)[20]. The RT-PCR products amplified from fractions before (R0) or af‐
ter one round (R1) of selection were analyzed by agarose gel electrophoresis. (C) In vitro selection of protein-drug in‐
teractions was performed using a mixture of two genes with N-terminal T7 tag and C-terminal FLAG-tag coding
sequences: fkbp12 (448 bp) and a p53 (15-29 aa) fragment (175 bp). The template RNAs of fkbp12 and the p53 frag‐
ment (negative control) were mixed at a ratio of 1:106. The mixtures were translated and the resulting IVV libraries
were selected on the sensor chip conjugated with bait drug (FK506)[71]. The RT-PCR products amplified from frac‐
tions before (R0) or after one round (R1) of selection were analyzed by agarose gel electrophoresis.
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analysis of protein-protein, protein-DNA and protein-drug interactions in proteomic and
therapeutic fields, and rapid evolution of novel artificial proteins from large randomized
libraries that often require ten or more rounds of selection.
5. Highly sensitive, high-throughput cDNA tiling arrays for detecting
protein interactions selected by the IVV method
The most serious bottleneck in the IVV method has been in the final decoding step to identify
the selected protein sequences. This step is usually achieved by cloning in bacteria and DNA
sequencing using Sanger sequencers, but the following difficulties arise: 1) Only a limited
number of clones can be analyzed, and thus positive candidates whose contents in the selected
library are less than a threshold determined by the number of analyzed clones are lost as false
negatives. 2) Positive sequences with low contents in a library can be enriched by iterative
rounds of affinity selection, but lower-affinity binders compete with higher-affinity binders
and therefore drop out of the screening. 3) DNA fragments which are injurious to cloning hosts,
e.g., cytotoxic sequences, may be lost. 4) Cloning and sequencing of a huge number of copies
of selected sequences is redundant, cost-ineffective, and time-consuming.
A DNA microarray is an efficient substitute for the cloning and sequencing processes to
overcome the above limitations (Fig. 8). The combined use of a tiling array [82] representing
ORF sequences with the IVV method would provide a completely in vitro platform for highly
sensitive and parallel analysis of protein interactions. It should be possible to detect enrichment
of cDNA fragments of selected candidates even with low contents or low affinity. However,
for the analyses, the tiling arrays should be custom-designed specifically for the IVV screening,
because the DNA fragments from the IVV method have unique characteristics, e.g., short
length and functional region-concentrated distribution [16]. In this chapter, we introduce a
 
Figure 8. Schematic representation of the tiling array method and a conventional method for sequence determina‐
tion of cDNAs from IVV screening.
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highly sensitive, high-throughput protein interaction analysis procedure combining the IVV
method with tiling arrays.
First, we designed a custom oligo DNA microarray as follows: 1) Oligonucleotide probes of
50-mer in length were used. This is the preferred length for microarray probes, because shorter
probes result in low sensitivity and longer probes produce non-specific signals [83]. 2) There
should be no gaps between the probes. A contiguous linear series of data is required to
recognize a signal peak in the algorithm for tiling array analysis, as described below, so the
probes must be densely arranged. 3) mRNA sequences were employed for the tiling array.
Only coding regions are required for the purpose of protein-interaction analysis, so other
genomic sequences, e.g., introns, control regions and non-coding RNAs, were not employed.
Second, we also improved the method for labeling of cDNA samples. Usually, double-stranded
DNA samples for a tiling array analysis are labeled by using random primers [84]. However,
cDNA fragments selected from a randomly fragmented cDNA library [16] seem to be too short
for efficient labeling by random priming. Indeed, in a test analysis with a tiling array using the
random priming labeling method, we failed to detect any of the previously detected positive
controls. Therefore we employed another labeling procedure [85], in which sense-strand-
labeled
RNAs were produced by one-step in vitro transcription using a SP6 promoter attached to cDNA
fragments from IVV screening.
 
Figure 9. Windowed threshold detection algorithm for signal peak detection.
Third, we developed a detection algorithm for specific signal peaks from raw data. After
iterative rounds of IVV screening, the resulting cDNA libraries in the presence and absence
of bait  protein,  called bait  (+)  and bait  (-)  library,  respectively,  are labeled with fluores‐
cence dyes using the above method,  and hybridized separately.  The ratios of  the signal
intensities from the experiments in the presence and absence of bait were calculated. Next,
we  searched  for  signal  peaks  in  the  data  using  the  “windowed  threshold  detection”
algorithm  (Fig.  9).  This  algorithm  looks  for  at  least  four  data  points  that  are  above  a
threshold value within a window. These points were grouped together and presented as
a peak.  We used the following parameters in the algorithm: peak window size,  300 bp;
percent of peak threshold, 20% of maximum data in each mRNA sequence. The value of
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each peak was the maximum value of the data points in that peak. Only reproducible peaks
in the duplicated data were collected as candidates.
As an actual model study, we performed protein-protein interaction screening for mouse Jun
protein [86], a transcription factor containing a bZIP domain, using the combined IVV and
tilling array method. For this study, we constructed a novel custom microarray containing
~1,600 ORF sequences of known and predicted mouse transcription-regulatory factors (334,372
oligonucleotides) [16,87,88] to analyze cDNA fragments from IVV screening for Jun-interac‐
tors, and named it the Transcription-Factor Tiling (TFT) array. From the 5th-round DNA
library of the IVV screening in the presence and absence of a bait Jun protein, we obtained
labeled RNAs and hybridized them onto the TFT array [89].
Positive signal peaks were collected using the windowed threshold detection algorithm; the
total number of peaks was 647 on 545 mRNA sequences (some of the mRNA sequences
included multiple peaks) [89]. An example is shown in Fig. 10. To distinguish between true
positives and false positives, specific enrichment of the selected candidate was validated by
real-time PCR. Among the top 10 percent of the peaks (64 regions), specific enrichment of 35
peaks was confirmed in the screening (white bars in Fig. 11A). The data indicate that the
appropriate threshold for distinguishing between true positives and noise in the microarray
signal is a signal ratio of 3~4. The 35 candidates identified in the present study include all of
the 20 Jun-interactors identified in our previous studies using conventional cloning and
sequencing [16,88]. Furthermore, the 35 candidates include eight well-known Jun-associated
proteins, which is double the number in the previous study, in which four known Jun-
interactors were obtained (white bars of Fig. 11B) [16,88,89]. In other words, 15 proteins
including four known Jun-interactors were newly detected using the TFT arrays.
 
Figure 10. An example of probe signals and a detected signal peak on a gene.
Finally,  we used in vitro  pulldown assay and the surface plasmon resonance method to
confirm the  physical  association  of  the  11  newly  discovered  candidates  with  Jun.  As  a
result, ten of the 11 tested candidates exhibited specific interaction with the bZIP domain
of Jun. Although most of the above tested interactions seem to be very weak, we consid‐
ered that the interactions are true positives, because all  of the candidates except for one
contain leucine-heptad repeats in the selected regions, and such repeats are an important
motif for heterodimerization with Jun [89].
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Previous studies and our survey revealed that the cDNA library used in this screening con‐
tained 29 known Jun-interactors [89,90]. Of these proteins, four (14%) and eight (28%) were de‐
tected by conventional sequencing and by the TFT array method, respectively. Thus, the TFT
array method provides a remarkable increase in the number of identified interactors and this
confirms the value of our new methodology as a screening tool for protein interactions. While
the coverage was increased considerably, the accuracy did not decrease. Specifically, the num‐
ber of false positives did not increase: the rates of confirmation of proteins by in vitro pull-
down assays  in  the  previous  and present  studies  were  75% and 74%,  respectively  [90].
Undetected remaining interactors were considered to be false negatives. Mismatching of the
selection conditions, e.g., salts, detergents, and pH, or the bait construct, e.g., length, region,
and tags, might inhibit these interactions.
For quantitative analysis, the abundance ratios of 35 specifically selected candidates in the in‐
itial and screened cDNA libraries were determined by real-time PCR, and the enrichment rates
(abundance ratio in the 5th round library per that in the initial library) were also calculated
[88,89]. The abundance of the 15 newly found candidates (excluding four cases) was less than
the theoretical threshold determined from the results of our previous study (an analysis of 451
clones). In order to detect the least abundant candidate (1.3 x 10-4% of the screened cDNA li‐
brary) by cloning and sequencing, it would have been necessary to analyze at least 1.0 x 106
clones. These results indicate that our new method is more sensitive, higher-throughput and
more cost-effective than the previous method.
From the standpoint of the detection sensitivity, the combined use of the IVV method with til‐
ing arrays provides an extremely sensitive method for protein-interaction analysis, because
even a very weakly expressed target could be detected in this study. In the cDNA library be‐
fore IVV screening, the content of fragments of the selected region of the least abundant known
Jun-binder was 1.2 x 10-7%. If one mRNA molecule existed per cell, the content of a fragment
of the gene would be about 1.2 x 10-5 to 5.9 x 10-5% (we employed reported parameters for this
calculation [91]). Thus, the content of the least abundant mRNA in the initial library corre‐
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Figure 11. Data from the TFT array. (A) The top 10% of candidates were confirmed by real-time PCR. White and gray
indicate numbers of enriched and non-enriched candidates, respectively. (B) Numbers of known (white) and newly se‐
lected (gray) proteins from conventional sequencing and the TFT arrays.
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sponds to about one molecule per 20 to 100 cells. This suggests that this gene is expressed at
a very low level in a cell type that is a minor component of the tested tissue. It is noteworthy
that targets expressed at such low levels can be detected without the need for a cell purifica‐
tion procedure, e.g., collection of somatic stem cells by flow cytometry. The high sensitivity of
our method may allow access to targets which would be hard to analyze with other existing
tools, such as the TAP method [48].
In summary, we have applied tiling array technology, which has previously been used for
ChIP-chip assays and transcriptome analyses, to protein-interaction analysis with the IVV
method. Compared with previous results obtained with cloning and sequencing, the use of
the tiling array greatly increased sensitivity. This method can detect targets expressed at ex‐
tremely low levels. This highly sensitive and reliable method has the potential to be used wide‐
ly, because the tiling array approach can easily be extended to a genome-wide scale, even
though the search space is limited in tiled sequences.
6. Conclusion
We have developed an mRNA display technology, named the in vitro virus (IVV) method, as
a stable and efficient tool for analyzing various protein functions. The IVV method is applicable
for exploring protein complexes, transcription factors, RNA-binding proteins, bioactive
peptides, drug-target proteins and antibodies, as well as in vitro protein evolution from
random-sequence and block-shuffling libraries. We further developed a large-scale and high-
throughput IVV screening system utilizing a biorobot, microfluidic tip, and tiling array. Here
we reviewed applications of the IVV method for protein functional analyses.
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